{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:28:58Z","timestamp":1786984138894,"version":"build-2736575974"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.addr.2018.06.003","type":"journal-article","created":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T20:47:43Z","timestamp":1528404463000},"page":"34-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Inhalation of repurposed drugs to treat pulmonary hypertension"],"prefix":"10.1016","volume":"133","author":[{"given":"Tobias","family":"Gessler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2018.06.003_bb0005","doi-asserted-by":"crossref","first-page":"D42","DOI":"10.1016\/j.jacc.2013.10.032","article-title":"Definitions and diagnosis of pulmonary hypertension","volume":"62","author":"Hoeper","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.addr.2018.06.003_bb0010","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1183\/09031936.00145608","article-title":"Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review","volume":"34","author":"Kovacs","year":"2009","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2018.06.003_bb0015","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1183\/13993003.01032-2015","volume":"46","author":"Gali\u00e8","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2018.06.003_bb0020","doi-asserted-by":"crossref","first-page":"D34","DOI":"10.1016\/j.jacc.2013.10.029","article-title":"Updated clinical classification of pulmonary hypertension","volume":"62","author":"Simonneau","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.addr.2018.06.003_bb0025","doi-asserted-by":"crossref","first-page":"D100","DOI":"10.1016\/j.jacc.2013.10.033","article-title":"Pulmonary hypertension due to left heart diseases","volume":"62","author":"Vachi\u00e9ry","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.addr.2018.06.003_bb0030","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1093\/eurheartj\/ehs109","article-title":"Guidelines on the management of valvular heart disease (version 2012)","volume":"33","author":"Vahanian","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.addr.2018.06.003_bb0035","doi-asserted-by":"crossref","first-page":"D51","DOI":"10.1016\/j.jacc.2013.10.023","article-title":"Pulmonary arterial hypertension: epidemiology and registries","volume":"62","author":"McGoon","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.addr.2018.06.003_bb0040","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1183\/09031936.00092306","article-title":"An epidemiological study of pulmonary arterial hypertension","volume":"30","author":"Peacock","year":"2007","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2018.06.003_bb0045","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","article-title":"Pulmonary arterial hypertension in France: results from a national registry","volume":"173","author":"Humbert","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0050","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension. Results from a national prospective registry","volume":"115","author":"D'Alonzo","year":"1991","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0055","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/CIRCULATIONAHA.109.911818","article-title":"Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era","volume":"122","author":"Humbert","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2018.06.003_bb0060","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1378\/chest.11-1460","article-title":"An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry","volume":"142","author":"Benza","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.addr.2018.06.003_bb0065","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1067\/mlc.2001.119329","article-title":"Physiologic basis for the treatment of pulmonary hypertension","volume":"138","author":"Olschewski","year":"2001","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0070","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","article-title":"Expression of endothelin-1 in the lungs of patients with pulmonary hypertension","volume":"328","author":"Giaid","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0075","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199207093270202","article-title":"An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension","volume":"327","author":"Christman","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0080","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJM199507273330403","article-title":"Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension","volume":"333","author":"Giaid","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0085","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/thoraxjnl-2015-207170","article-title":"The molecular targets of approved treatments for pulmonary arterial hypertension","volume":"71","author":"Humbert","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.addr.2018.06.003_bb0090","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1161\/CIRCULATIONAHA.114.006974","article-title":"Advances in therapeutic interventions for patients with pulmonary arterial hypertension","volume":"130","author":"Humbert","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2018.06.003_bb0095","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1164\/rccm.201201-0164OC","article-title":"Modern age pathology of pulmonary arterial hypertension","volume":"186","author":"Stacher","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0100","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ccm.2013.08.009","article-title":"Pathology of pulmonary hypertension","volume":"34","author":"Tuder","year":"2013","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0105","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1055\/s-0037-1606214","article-title":"Pathology and pathobiology of pulmonary hypertension","volume":"38","author":"Guignabert","year":"2017","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0110","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1164\/rccm.201308-1543PP","article-title":"Novel and emerging therapies for pulmonary hypertension","volume":"189","author":"Pullamsetti","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0115","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrcardio.2011.87","article-title":"Mechanisms of disease: pulmonary arterial hypertension","volume":"8","author":"Schermuly","year":"2011","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.addr.2018.06.003_bb0120","article-title":"Emerging therapeutics in pulmonary hypertension","author":"Hensley","year":"2018","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"key":"10.1016\/j.addr.2018.06.003_bb0125","doi-asserted-by":"crossref","first-page":"128","DOI":"10.4103\/2045-8932.109951","article-title":"Mechanics and mechanisms of pulmonary hypertension-Conference summary and translational perspectives","volume":"3","author":"Seeger","year":"2013","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.addr.2018.06.003_bb0130","doi-asserted-by":"crossref","first-page":"225S","DOI":"10.1378\/chest.114.3_Supplement.225S","article-title":"Primary pulmonary hypertension between inflammation and cancer","volume":"114","author":"Voelkel","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.addr.2018.06.003_bb0135","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1183\/09059180.00007513","article-title":"Pathogenesis of pulmonary arterial hypertension: lessons from cancer","volume":"22","author":"Guignabert","year":"2013","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.addr.2018.06.003_bb0140","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijcard.2010.07.003","article-title":"Vascular remodeling in pulmonary arterial hypertension: multiple cancer-like pathways and possible treatment modalities","volume":"147","author":"Sakao","year":"2011","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.addr.2018.06.003_bb0145","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1164\/rccm.200709-1369PP","article-title":"The cancer paradigm of severe pulmonary arterial hypertension","volume":"178","author":"Rai","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0150","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1164\/rccm.201606-1226PP","article-title":"Translational advances in the field of pulmonary hypertension. From cancer biology to new pulmonary arterial hypertension therapeutics. Targeting cell growth and proliferation signaling hubs","volume":"195","author":"Pullamsetti","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0155","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aai9048","article-title":"Lung cancer-associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cell-immune cell cross-talk","volume":"9","author":"Pullamsetti","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0160","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1172\/JCI24838","article-title":"Reversal of experimental pulmonary hypertension by PDGF inhibition","volume":"115","author":"Schermuly","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2018.06.003_bb0165","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMc051946","article-title":"Imatinib for the treatment of pulmonary arterial hypertension","volume":"353","author":"Ghofrani","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0170","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1164\/rccm.201001-0123OC","article-title":"Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy","volume":"182","author":"Ghofrani","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0175","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.112.000765","article-title":"Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study","volume":"127","author":"Hoeper","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2018.06.003_bb0180","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.healun.2015.05.025","article-title":"Long-term safety and efficacy of imatinib in pulmonary arterial hypertension","volume":"34","author":"Frost","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.addr.2018.06.003_bb0185","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/nm.3695","article-title":"Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension","volume":"20","author":"Savai","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0190","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/35065611","article-title":"NO-independent regulatory site on soluble guanylate cyclase","volume":"410","author":"Stasch","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.addr.2018.06.003_bb0195","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/263663a0","article-title":"An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation","volume":"263","author":"Moncada","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.addr.2018.06.003_bb0200","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/0090-6980(76)90125-8","article-title":"Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation","volume":"12","author":"Bunting","year":"1976","journal-title":"Prostaglandins"},{"key":"10.1016\/j.addr.2018.06.003_bb0205","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/0090-6980(76)90126-X","article-title":"The chemical structure of prostaglandin X (prostacyclin)","volume":"12","author":"Whittaker","year":"1976","journal-title":"Prostaglandins"},{"key":"10.1016\/j.addr.2018.06.003_bb0210","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1016\/S0021-9258(18)32859-X","article-title":"Purification of prostacyclin synthase from bovine aorta by immunoaffinity chromatography. Evidence that the enzyme is a hemoprotein","volume":"258","author":"DeWitt","year":"1983","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2018.06.003_bb0215","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1006\/excr.1995.1259","article-title":"Prostacyclin (PGI2) synthase is a constitutively expressed enzyme in human endothelial cells","volume":"219","author":"Spisni","year":"1995","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.addr.2018.06.003_bb0220","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.pharmthera.2004.01.003","article-title":"Prostacyclin and its analogues in the treatment of pulmonary hypertension","volume":"102","author":"Olschewski","year":"2004","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.addr.2018.06.003_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/jamp.2007.0657","article-title":"Inhaled prostanoids in the therapy of pulmonary hypertension","volume":"21","author":"Gessler","year":"2008","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2018.06.003_bb0230","first-page":"414P","article-title":"Disappearance of prostacyclin (PGI2) in the circulation of the dog [proceedings]","volume":"62","author":"Dusting","year":"1978","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.addr.2018.06.003_bb0235","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1021\/ja00448a069","article-title":"Synthesis of Vane's prostaglandin X, 6,9.alpha.-oxido-9.alpha.,15.alpha.-dihydroxyprosta-(Z)5,(E)13-dienoic acid","volume":"99","author":"Corey","year":"1977","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2018.06.003_bb0240","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1021\/ja00454a060","article-title":"Synthesis and stereochemistry of prostacyclin and synthesis of 6-oxo-prostaglandin F1\u03b1","volume":"99","author":"Johnson","year":"1977","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2018.06.003_bb0245","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1016\/S0040-4039(01)83078-1","article-title":"A synthesis of prostacyclin sodium salt","volume":"32","author":"Whittaker","year":"1977","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.addr.2018.06.003_bb0250","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0031-6997(25)06759-6","article-title":"Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin","volume":"30","author":"Moncada","year":"1978","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.addr.2018.06.003_bb0255","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1161\/01.HYP.12.6.530","article-title":"Mediators produced by the endothelial cell","volume":"12","author":"Gryglewski","year":"1988","journal-title":"Hypertension"},{"key":"10.1016\/j.addr.2018.06.003_bb0260","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0049-3848(78)90004-X","article-title":"Anti-platelet action of intravenous infusion of prostacyclin in man","volume":"13","author":"Gryglewski","year":"1978","journal-title":"Thromb. Res."},{"key":"10.1016\/j.addr.2018.06.003_bb0265","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1056\/NEJM199007053230106","article-title":"Regulatory functions of the vascular endothelium","volume":"323","author":"Vane","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0270","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1078-5884(03)00385-X","article-title":"Prostacyclin: a vascular mediator","volume":"26","author":"Vane","year":"2003","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"10.1016\/j.addr.2018.06.003_bb0275","article-title":"PGI2 as a regulator of inflammatory diseases","volume":"926968","author":"Dorris","year":"2012","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.addr.2018.06.003_bb0280","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.prostaglandins.2006.05.011","article-title":"Cardioprotective prostacyclin signaling in vascular smooth muscle","volume":"82","author":"Fetalvero","year":"2007","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.addr.2018.06.003_bb0285","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1183\/09031936.00097107","article-title":"Prostacyclin therapies for the treatment of pulmonary arterial hypertension","volume":"31","author":"Gomberg-Maitland","year":"2008","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2018.06.003_bb0290","doi-asserted-by":"crossref","first-page":"205S","DOI":"10.1378\/chest.114.3_Supplement.205S","article-title":"Lipid mediator dysregulation in primary pulmonary hypertension","volume":"114","author":"Christman","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.addr.2018.06.003_bb0295","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1164\/ajrccm.159.6.9804054","article-title":"Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension","volume":"159","author":"Tuder","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0300","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1136\/hrt.44.3.254","article-title":"Haemodynamic changes induced by prostacyclin in man","volume":"44","author":"Szczeklik","year":"1980","journal-title":"Br. Heart J."},{"key":"10.1016\/j.addr.2018.06.003_bb0305","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/hrt.45.4.385","article-title":"Haemodynamic effects of prostacyclin (PGI2) in pulmonary hypertension","volume":"45","author":"Guadagni","year":"1981","journal-title":"Br. Heart J."},{"key":"10.1016\/j.addr.2018.06.003_bb0310","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1161\/01.CIR.66.2.334","article-title":"Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension","volume":"66","author":"Rubin","year":"1982","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2018.06.003_bb0315","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0140-6736(84)91452-1","article-title":"Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin)","volume":"1","author":"Higenbottam","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2018.06.003_bb0320","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1136\/hrt.70.4.366","article-title":"Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension","volume":"70","author":"Higenbottam","year":"1993","journal-title":"Br. Heart J."},{"key":"10.1016\/j.addr.2018.06.003_bb0325","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7326\/0003-4819-112-7-485","article-title":"W. Long, Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial","volume":"112","author":"Rubin","year":"1990","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0330","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/0003-4819-121-6-199409150-00003","article-title":"Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin","volume":"121","author":"Barst","year":"1994","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0335","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0735-1097(97)00187-3","article-title":"Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion","volume":"30","author":"Shapiro","year":"1997","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.addr.2018.06.003_bb0340","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1183\/09031936.99.13613579","article-title":"Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study","volume":"13","author":"Humbert","year":"1999","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2018.06.003_bb0345","doi-asserted-by":"crossref","first-page":"740","DOI":"10.7326\/0003-4819-130-9-199905040-00014","article-title":"Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series","volume":"130","author":"McLaughlin","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0350","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"Primary Pulmonary Hypertension Study Group, A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0355","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0360","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","article-title":"Survival in primary pulmonary hypertension: the impact of epoprostenol therapy","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2018.06.003_bb0365","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","article-title":"Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival","volume":"40","author":"Sitbon","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.addr.2018.06.003_bb0370","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0055-2016","article-title":"Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience","volume":"26","author":"Sitbon","year":"2017","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.addr.2018.06.003_bb0375","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1742-1241.2010.02525.x","article-title":"How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension?","volume":"64","author":"Barst","year":"2010","journal-title":"Int. J. Clin. Pract. Suppl."},{"key":"10.1016\/j.addr.2018.06.003_bb0380","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ahj.2013.08.007","article-title":"EPITOME-2: an open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension","volume":"167","author":"Sitbon","year":"2014","journal-title":"Am. Heart J."},{"key":"10.1016\/j.addr.2018.06.003_bb0385","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1365-2125.1982.tb01959.x","article-title":"Side effects occurring during administration of epoprostenol (prostacyclin, PGI2) in man","volume":"14","author":"Pickles","year":"1982","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2018.06.003_bb0390","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1378\/chest.122.1.378","article-title":"Severe erythroderma as a complication of continuous epoprostenol therapy","volume":"122","author":"Ahearn","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.addr.2018.06.003_bb0395","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1056\/NEJM199801293380501","article-title":"Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension","volume":"338","author":"McLaughlin","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0400","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1378\/chest.126.1.90","article-title":"Micrococcus-associated central venous catheter infection in patients with pulmonary arterial hypertension","volume":"126","author":"Oudiz","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.addr.2018.06.003_bb0405","doi-asserted-by":"crossref","first-page":"67A","DOI":"10.1016\/S0002-9149(99)80386-5","article-title":"Role of prostacyclin in the treatment of primary pulmonary hypertension","volume":"75","author":"Cremona","year":"1995","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.addr.2018.06.003_bb0410","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ddstr.2011.07.001","article-title":"Formulation technology to repurpose drugs for inhalation delivery","volume":"8","author":"Cipolla","year":"2011","journal-title":"Drug Discov. Today Ther. Strateg."},{"key":"10.1016\/j.addr.2018.06.003_bb0415","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Aerosolized Iloprost randomized study group, inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0420","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/0140-6736(93)92004-D","article-title":"Aerosolised prostacyclin in adult respiratory distress syndrome","volume":"342","author":"Walmrath","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2018.06.003_bb0425","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1164\/ajrccm.153.3.8630585","article-title":"Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome","volume":"153","author":"Walmrath","year":"1996","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0430","first-page":"724","article-title":"Effects of aerosolized prostacyclin in severe pneumonia. Impact of fibrosis","volume":"151","author":"Walmrath","year":"1995","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0435","doi-asserted-by":"crossref","first-page":"820","DOI":"10.7326\/0003-4819-124-9-199605010-00006","article-title":"Aerosolized prostacyclin and iloprost in severe pulmonary hypertension","volume":"124","author":"Olschewski","year":"1996","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0440","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0735-1097(99)00494-5","article-title":"A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension","volume":"35","author":"Hoeper","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.addr.2018.06.003_bb0445","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1164\/ajrccm.160.2.9810008","article-title":"Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis","volume":"160","author":"Olschewski","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0450","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s001340050628","article-title":"Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost","volume":"24","author":"Olschewski","year":"1998","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0455","doi-asserted-by":"crossref","first-page":"435","DOI":"10.7326\/0003-4819-132-6-200003210-00003","article-title":"Inhaled iloprost to treat severe pulmonary hypertension: an uncontrolled trial","volume":"132","author":"Olschewski","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0460","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1378\/chest.124.4.1294","article-title":"Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension","volume":"124","author":"Olschewski","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.addr.2018.06.003_bb0465","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1183\/09031936.01.17100140","article-title":"Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension","volume":"17","author":"Gessler","year":"2001","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2018.06.003_bb0470","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1089\/089426802320282239","article-title":"Aerosolized vasodilators in pulmonary hypertension","volume":"15","author":"Gessler","year":"2002","journal-title":"J. Aerosol Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0475","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1164\/rccm.200603-358OC","article-title":"Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension","volume":"174","author":"McLaughlin","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0480","doi-asserted-by":"crossref","first-page":"515","DOI":"10.7326\/0003-4819-136-7-200204020-00008","article-title":"Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension","volume":"136","author":"Ghofrani","year":"2002","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0485","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0735-1097(03)00555-2","article-title":"Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension","volume":"42","author":"Ghofrani","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.addr.2018.06.003_bb0490","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJM200006223422503","article-title":"Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue","volume":"342","author":"Hoeper","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0495","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/eurheartj\/ehi283","article-title":"Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension","volume":"26","author":"Opitz","year":"2005","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.addr.2018.06.003_bb0500","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.rmed.2010.01.008","article-title":"Long-term therapy with inhaled iloprost in patients with pulmonary hypertension","volume":"104","author":"Olschewski","year":"2010","journal-title":"Respir. Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0505","doi-asserted-by":"crossref","first-page":"381","DOI":"10.4103\/2045-8932.114768","article-title":"A multicenter, retrospective study of patients with pulmonary arterial hypertension transitioned from parenteral prostacyclin therapy to inhaled iloprost","volume":"3","author":"Channick","year":"2013","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.addr.2018.06.003_bb0510","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jjcc.2016.07.002","article-title":"Effects of long-term iloprost treatment on right ventricular function in patients with Eisenmenger syndrome","volume":"69","author":"Chon","year":"2017","journal-title":"J. Cardiol."},{"key":"10.1016\/j.addr.2018.06.003_bb0515","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1093\/cvr\/cvx148","article-title":"Treatment strategies for the right heart in pulmonary hypertension","volume":"113","author":"Westerhof","year":"2017","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.addr.2018.06.003_bb0520","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/ajhp\/60.9.916","article-title":"Stability and preservative effectiveness of treprostinil sodium after dilution in common intravenous diluents","volume":"60","author":"Phares","year":"2003","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.addr.2018.06.003_bb0525","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00005344-200408000-00010","article-title":"Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers","volume":"44","author":"Laliberte","year":"2004","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.addr.2018.06.003_bb0530","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0535","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1378\/chest.129.6.1636","article-title":"Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension","volume":"129","author":"Lang","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.addr.2018.06.003_bb0540","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1183\/09031936.06.00044406","article-title":"Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil","volume":"28","author":"Barst","year":"2006","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2018.06.003_bb0545","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.healun.2009.09.005","article-title":"Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial","volume":"29","author":"Hiremath","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.addr.2018.06.003_bb0550","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FJC.0b013e31802b3184","article-title":"Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension","volume":"49","author":"Sitbon","year":"2007","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.addr.2018.06.003_bb0555","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1378\/chest.129.3.683","article-title":"Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial","volume":"129","author":"Tapson","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.addr.2018.06.003_bb0560","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.112.124388","article-title":"Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial","volume":"127","author":"Jing","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2018.06.003_bb0565","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1378\/chest.12-2875","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial","volume":"144","author":"Tapson","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.addr.2018.06.003_bb0570","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1378\/chest.11-2212","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and\/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial","volume":"142","author":"Tapson","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.addr.2018.06.003_bb0575","doi-asserted-by":"crossref","first-page":"149","DOI":"10.7326\/0003-4819-144-2-200601170-00026","article-title":"Inhaled treprostinil [corrected] for treatment of chronic pulmonary arterial hypertension","volume":"144","author":"Voswinckel","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0580","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.jacc.2006.06.062","article-title":"Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies","volume":"48","author":"Voswinckel","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.addr.2018.06.003_bb0585","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pupt.2008.11.009","article-title":"Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension","volume":"22","author":"Voswinckel","year":"2009","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2018.06.003_bb0590","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.pupt.2008.07.003","article-title":"Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension","volume":"21","author":"Voswinckel","year":"2008","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2018.06.003_bb0595","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.jacc.2006.05.070","article-title":"Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension","volume":"48","author":"Channick","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.addr.2018.06.003_bb0600","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.addr.2018.06.003_bb0605","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.healun.2011.08.019","article-title":"Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil sodium inhalation used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension","volume":"30","author":"Benza","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.addr.2018.06.003_bb0610","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/2045893217706691","article-title":"The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension","volume":"7","author":"Gessler","year":"2017","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.addr.2018.06.003_bb0615","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/1753465810397693","article-title":"The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension","volume":"5","author":"Gessler","year":"2011","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.addr.2018.06.003_bb0620","doi-asserted-by":"crossref","DOI":"10.3390\/jcm6050048","article-title":"Nanoparticle-mediated drug delivery system for pulmonary arterial hypertension","volume":"6","author":"Nakamura","year":"2017","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0625","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/MCP.0000000000000404","article-title":"New targets for pulmonary arterial hypertension: going beyond the currently targeted three pathways","volume":"23","author":"Huertas","year":"2017","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0630","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.molmed.2016.11.005","article-title":"Targeting vascular remodeling to treat pulmonary arterial hypertension","volume":"23","author":"Thompson","year":"2017","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.addr.2018.06.003_bb0635","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.pharmthera.2013.10.002","article-title":"Targeted therapies in pulmonary arterial hypertension","volume":"141","author":"Montani","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.addr.2018.06.003_bb0640","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pupt.2017.08.002","article-title":"Effects of fasudil on pulmonary hypertension in clinical practice","volume":"46","author":"Zhang","year":"2017","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2018.06.003_bb0645","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s00380-009-1176-8","article-title":"Acute vasodilator effects of inhaled fasudil, a specific rho-kinase inhibitor, in patients with pulmonary arterial hypertension","volume":"25","author":"Fujita","year":"2010","journal-title":"Heart Vessel."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X18301406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X18301406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T21:19:44Z","timestamp":1751663984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X18301406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":129,"alternative-id":["S0169409X18301406"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2018.06.003","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhalation of repurposed drugs to treat pulmonary hypertension","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2018.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}